Explore Bladder Cancer Studies
SURF 302
Ablative therapy trial for patients with LG IR NMIBC. All patients must have 3-12mm of remaining tumor, have current proven LG disease, test FGFR+ on current or previous path. Patients will be treated with Dabogratinib, an oral FGFR inhibitor.
ABLE-32
AUA IR NMIBC (including HG <3cm) will be randomized to Adstiladrin (intravesc 1x q3mo) vs observation. Patients on observation who have an IR recurrence can crossover to treatment.
AUA-Intermediate
Protara III
BCG naïve (or no BCG in last 2yrs or 2 or fewer doses of BCG in the last 2yrs) CIS +/- papillary disease. Patients are randomized to TARA-002 (which is similar to BCG but composed of strep pyogenes) vs intravesical chemo – both given via induction and maintenance. Crossover allowed.
Moonrise 3
BCG exposed, unresponsive, or intolerant pure papillary disease. Must test FGFR positive. Patients will randomize to TAR-210 (pretzel device) with Erdafitanib (FGFR inhibitor) exchanged q3mo vs intravesical chemo induction and q1mo maintenance.
CORE-8 (Paused Enrollment)
Cohort B – HR BCG exposed patients with CIS or papillary disease, all patients will have Cretostimogene
Protara Advanced 2
BCG unresponsive (by the FDA definition, must have had at least 5 of 6 induction rounds and 2 of 3 maintenance or 2 of 6 reinduction) CIS. All patients will have TARA-002 which is similar to BCG but composed of strep pyogenes – given via induction and maintenance.
ABLE 22
A phase 2, randomized, multi-centre, open-label trial to evaluate the safety and efficacy of intravesical nadofaragene firadenovec alone or in combination with chemotherapy (gemcitabine and docetaxel) or immunotherapy (pembrolizumab) in subjects with high-grade Bacillus Calmette-Guerin unresponsive non-muscle invasive bladder cancer
AUA - High Risk
Merck V940
A Phase 2 Open-label Randomized Study of V940 in Combination With BCG Versus BCG Monotherapy in Participants With High-risk Non-muscle Invasive Bladder Cancer (INTerpath-011)
BCG Intolerant and CIS
UroGen UT-002
A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-104, a Novel Formulation of UGN-101, for the Treatment of Patients With Low-grade Upper Tract Urothelial Cancer (LG-UTUC)
Low grade upper tract disease